Salute e Benessere

Piramal Pharma Solutions Announces $80M Expansion Plan for Sterile Injectables…

"This expansion represents a strategic investment in the future of Piramal Pharma Ltd. Filling the commercial manufacturing gap enables the Lexington site to access the rapidly expanding injectables market and establish itself as a key player in the segment," said Nandini Piramal, Chairperson, Piramal Pharma Ltd. "This expansion represents a strategic investment in the future of Piramal Pharma Ltd. Filling the commercial manufacturing gap enables theLexingtonsite to access the…
PR Newswire
30/09/2024

Total number of shares and voting rights in Zealand Pharma A/S on September 30…

Company announcement – No. 46 / 2024 Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 Copenhagen, Denmark, September 30, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company...
Nasdaq GlobeNewswire
30/09/2024

SONGMICS HOME Supports Jugendrotkreuz's Milestone Event to Promote First Aid and…

Daisy Wei, Senior Brand Manager of SONGMICS HOME, highlighted that partnering with Jugendrotkreuz represents a significant opportunity to promote first aid skills and the values of volunteer service. This initiative seeks to benefit more individuals, working together toward a better tomorrow. Daisy Wei, Senior Brand Manager of SONGMICS HOME, highlighted that partnering with Jugendrotkreuz represents a significant opportunity to promote first aid skills and the values of volunteer service...
PR Newswire
30/09/2024

ACL Graft Market to Hit USD 0.18 Billion by 2029 with 7.2% CAGR |…

Browse in-depth TOC on "ACL Graft Market" Browse in-depth TOC on "ACL Graft Market" 234 - Tables 36 - Figures 209 - Pages The primary ACL reconstruction and ACL revision segments of the global ACL graft market are based on the type of ACL surgery. With a majority share, the ACL revision category led the ACL graft market in 2023. The demand for ACL grafts is expected to expand as the number of ACL reconstruction failures increases and there is a greater need for better…
PR Newswire
30/09/2024

LABCONNECT APPOINTS WESLEY P. WHEELER AS CHIEF EXECUTIVE OFFICER AND DIRECTOR

"Wes's deep industry knowledge and experience make him the perfect fit for LabConnect," said Tim Johnson, LabConnect's Chairman and Partner at BroadOak Capital. "We are thrilled to welcome him to the team and confident that he will lead the company to even greater achievements." "Wes's deep industry knowledge and experience make him the perfect fit for LabConnect," said Tim Johnson, LabConnect's Chairman and Partner at BroadOak Capital. "We are thrilled to…
PR Newswire
30/09/2024

Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer

Jan Adams succeeds Janneke van der Kamp, who will leave Grünenthal to pursue an opportunity outside the company. Jan AdamssucceedsJanneke van der Kamp, who will leave Grünenthal to pursue an opportunity outside the company. About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients...
PR Newswire
30/09/2024

IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral…

Casitas B-lineage lymphoma b (Cbl/b) is an E3 ubiquitin ligase that has been shown to be a key regulator of the activation of T and natural killer (NK) cells in the absence of CD28 costimulationGRC 65327 has been identified by IGI as a novel, nanomolar potent, selective, and orally bioavailable Cbl/b inhibitor NEW YORK, Sept.30, 2024(GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation (IGI), an alliance between Ichnos Sciences Inc., a global fully integrated clinical-stage...
Nasdaq GlobeNewswire
30/09/2024

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 30 September 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under…
Nasdaq GlobeNewswire
30/09/2024

Buyback of Class B shares in Essity during week 39, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
30/09/2024

Digital & Intelligent Pathway: Xiaohongshu and VOGUE Business Unveil…

Xiaohongshu, a trendsetting hub for brands to gain popularity, boasts a vast young consumer base and a high-quality content ecosystem. With deep insights into industry trends and user preferences, it has become the premier marketing platform for brands seeking to forge emotional connections with Chinese consumers. Xiaohongshu, a trendsetting hub for brands to gain popularity, boasts a vast young consumer base and a high-quality content ecosystem. With deep insights into industry trends and…
PR Newswire
30/09/2024

Xiaohongshu x VOGUE Business Unveils New Horizons in Healthcare and Wellness at…

Today, Xiaohongshu has established itself as a hub for sharing healthy lifestyles and a comprehensive resource for wellness enthusiasts. With a vibrant community of over 150 million health-conscious users, the social media platform has become a catalyst for trending topics such as skin brightening and anti-aging, healthy weight loss, hair care, nutritional balance, therapeutic exploration, and stress relief, underscoring the shift towards healthy lifestyles and health management, as well as new…
PR Newswire
30/09/2024

Xiaohongshu and VOGUE Business Redefine Home Aesthetics During Milan Fashion…

Aligning perfectly with Xiaohongshu's human-centric values, consumers are increasingly seeking harmony between their home environments and personal lifestyles. As a lifestyle community beloved by youth, the social media platform excels in understanding people's needs, gaining insights into emerging consumer scenarios and industry trends in China. According to Xiaohongshu Research, as of Q2 2024, with a monthly active user base of 300 million, nearly 65% of whom are passionate about home life…
PR Newswire
30/09/2024

SIFI announces allowance of patent on polihexanide for Europe and commercial…

The Patent grant follows SIFI's findings in the Phase 3 clinical trial, where AKANTIOR® (polihexanide 0.08%) demonstrated an 86% clinical resolution rate in AK, with an average time-to-cure of approximately 4 months. The Patent also covers the novel dosing regimen of 16 drops/day for first 5 days, 8 drops/day for the following 7 days, 6 drops/day for the following 7 days and 4 drops/day until clinical resolution. The proven dosing regimen represents also a major improvement in patients' quality…
PR Newswire
30/09/2024

Orion's near-term climate targets approved by the Science Based Targets…

ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2024 at 10.00 a.m. EEST Orion's near-term climate targets approved by the Science Based Targets initiative Orion Corporation is proud to announce that the Science Based Targets initiative (SBTi) has validated our near-term science-based targets. This means that our greenhouse gas (GHG) emissions reduction targets align with the latest climate science to limit global warming to 1.5°C above pre-industrial levels. Orion Corporation commitsto...
Nasdaq GlobeNewswire
30/09/2024

Change in number of shares and votes in Immunovia AB (publ)

Karin Almqvist Liwendahl, [email protected] +46 70 911 56 08 Karin Almqvist Liwendahl, [email protected] +46 70 911 56 08 This information is such information that Immunovia AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on 30 September 2024 at08:30 CET. Immunovia in brief Immunovia...
PR Newswire
30/09/2024

New number of shares and votes in Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn…
PR Newswire
30/09/2024

Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis…

Furthermore, the study results included the pathological regression rate (defined as the proportion of subjects with a pathological regression to CIN1 or normal tissue) at the 6th month across different age subgroups. Both the "≥20 and <30 years" subgroup and the "≥30 and <40 years" subgroup showed an increase of 15% to 20% in the pathological regression rate in the APL-1702 group compared to the placebo control group. No cervical cancer events were reported, suggesting…
PR Newswire
30/09/2024

BioSenic announces that it has started to look for new assets, the securing of…

PRIVILEGED INFORMATION Biosenic and Global Tech Opportunities 15 ("GTO 15") have entered into an amendment to the convertible bonds ("CB") agreement securing a further EUR 1.5 million of the programme, including at least two tranches of EUR 0.2 million net each. François Rieger and Véronique Pomi-Schneiter resign from their positions as CEO, chairman and executive director and non-executive director respectively, to focus on Medsenic. Finsys Management SRL, represented by its…
Nasdaq GlobeNewswire
30/09/2024

kdc/one strengthens its cosmetics packaging capabilities with the acquisition of…

Sandra Wisniewski, Global President Beauty and Personal Care at kdc/one, said: "This strategic acquisition significantly enhances our ability to offer innovative packaging solutions, complementing our comprehensive full-service capabilities that include ideation, design, formulation development, and manufacturing." Sandra Wisniewski, Global President Beauty and Personal Care at kdc/one, said: "This strategic acquisition significantly enhances our ability to offer innovative…
PR Newswire
30/09/2024

HSL CHAIRS : EXPERT REVEALS SITTING IN CORRECT SIZE CHAIR REDUCES BLOOD PRESSURE

The research also highlights that the right fitting chair reduces fidgeting, which contributes towards maintaining a good posture, limiting common aches and pains. The research also highlights that the right fitting chair reduces fidgeting, which contributes towards maintaining a good posture, limiting common aches and pains. Conducted by DrAndrea Utley, from the University's School of Biomedical Sciences, 24 participants, aged between 32 and 72, took part in the study. The...
PR Newswire
30/09/2024

Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results…

Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophreniaIndivior selected GABA B PAM drug candidate for development in substance use disordersAddex selected independent GABAB PAM drug candidate for development in chronic cough Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, September 30, 2024-Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of...
Nasdaq GlobeNewswire
30/09/2024

BioSenic reports half year 2024 results

REGULATED INFORMATION The interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Biosenic in the section 'Financial reports'. BioSenic publishes its interim financial report in English. A French translation of the report will also be made available. In the event of differences between the English and the French version of the...
Nasdaq GlobeNewswire
30/09/2024

DREAM Pivotal Study Data Presented at the International Surgical Sleep Society…

DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational UpdateAdditional clinical data on patients suffering from Obstructive Sleep Apnea (OSA) demonstrate a clinically significant 71.0% median reduction in Apnea-Hypopnea index (AHI) while sleeping supine at 12 months compared with baseline.82.0% of patients who completed a polysomnography at 12 months had an AHI below 15, and 67.4% of patients who completed a polysomnography at 12 months had...
Nasdaq GlobeNewswire
27/09/2024

Sectra enterprise imaging in the cloud to foster collaboration across 150 sites…

"I am honored by the trust MSSS Québec has placed in us in helping them enhance patient care across the province. This opportunity represents a significant milestone for Sectra in Canada and highlights our commitment to delivering innovative healthcare solutions. As we enter this exciting phase, we are excited about the possibilities that lie ahead. We will leverage our knowledge in deploying solutions for multi-site health systems to contribute to MSSS Québec's aim of significantly…
PR Newswire
27/09/2024
Altri  Comunicati